ArticleHaematologica2026

Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: "Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?"

Marco Picardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.